-1366x0.jpg)
Genetic Breakthroughs in Preimplantation Genetic Testing Being Applied in Europe and Vietnam
Assoc. Prof. Dr. Francesca Spinella explained that there are currently three widely used preimplantation genetic testing techniques being applied across Europe and globally: PGT-A, PGT-SR, and PGT-M. These primary methods help improve the success rates of in vitro fertilization (IVF) while reducing the risk of serious genetic disorders in future generations.
Among these, PGT-A helps detect chromosomal aneuploidy to screen out embryos that have abnormalities. This method has been proven to increase IVF success rates, decrease miscarriage rates, and ensure that the embryos implanted are the healthiest.
PGT-M is used to detect genetic mutations that could be inherited from parents, helping to avoid passing on common monogenic disorders like thalassemia, cystic fibrosis, Huntington's disease, and other genetic conditions. PGT-SR can detect structural chromosome abnormalities such as translocations, inversions, or deletions. These abnormalities can cause pregnancy complications and increase the risk of giving birth to a child with birth defects.
In addition to the widely implemented techniques, Assoc. Prof. Dr. Francesca Spinella mentioned two promising new methods that are being researched and developed in Europe: Non-invasive PGT-A (NiPGT-A) and PGT for ploidy (Ploidy). These breakthroughs are driven by the rapid development of genetic sequencing technologies, opening new possibilities for reproductive healthcare.
NiPGT-A represents a breakthrough in preimplantation genetic testing, allowing for testing without the need for embryo biopsy, thus minimizing potential risks to the embryo. This method detects chromosomal abnormalities in embryos from the culture medium, providing greater convenience and safety. Meanwhile, PGT for ploidy (Ploidy) is an advanced test that accurately determines the number of chromosomes in the embryo, helping to select embryos with a complete chromosomal set, thereby reducing the risk of reproductive issues or birth defects.
Assoc Prof. Dr. Francesca Spinella also expressed her deep impression with the preimplantation genetic testing methods being used in Vietnam. She stated that the expertise and modern facilities of the labs, especially at GENTIS, are on par with leading genetic testing centers worldwide.
Assoc Prof. Dr. Francesca Spinella Visits and Works at GENTIS Lab
In addition to common tests like PGT-A, PGT-M, and PGT-SR, GENTIS is also focusing on researching and developing two breakthrough techniques: PGT-Next and PGT-Upgrade. PGT-Next is an advanced method that combines the features of both PGT-A and PGT-SR, with the added capability of detecting chromosomal number abnormalities such as polyploidy and haploidy in embryos. This improves diagnostic accuracy, minimizes the risk of pregnancy with embryos that have chromosomal abnormalities, and optimizes the chances of a healthy pregnancy.
PGT-Upgrade is a significant advancement in genetic diagnosis of embryos. In addition to detecting abnormalities in chromosome number (PGT-A) and structure (PGT-SR), PGT-Upgrade can identify balanced chromosomal translocations passed from parents to embryos. This method helps detect hidden risks that PGT-A and PGT-SR cannot diagnose, while also identifying genetic factors that could affect the health of future generations. PGT-Upgrade offers superior advantages in selecting healthy embryos for artificial reproduction, thereby improving IVF success rates.
Strengthening Relationships and Promoting Multilateral Cooperation Among Global Healthcare Organizations
Promising Collaboration Between GENTIS and GENOMA
Through her visit and discussions, Assoc. Prof. Dr. Francesca Spinella noted that Vietnam’s healthcare services, particularly in reproductive medicine, have significant potential for growth. She emphasized that this event not only provided an opportunity to exchange ideas on advancements in genetic testing but also served as a clear testament to the sustainable and strategic partnership between GENTIS and GENOMA, both members of the Eurofins family. The cooperation between GENTIS and GENOMA is not based solely on commercial interests but also on the shared commitment to scientific research and advanced technologies. Both organizations share values in improving reproductive health and providing accurate and reliable genetic testing services for families and healthcare professionals in their reproductive health journeys.
This collaboration also allows GENTIS to access the latest genetic testing technologies and implement them in Vietnam, enhancing the quality of reproductive healthcare services domestically and contributing to the development of the genetic testing industry in Southeast Asia. GENTIS’s clients will now benefit from advanced genetic testing services, which offer the opportunity for healthy childbirth and minimize risks during pregnancy.
